1. Fas Ligand Reduces Viability in Primary Melanoma Short-Term Cell Cultures More than in Metastatic Melanoma Short-Term Cell Cultures
- Author
-
Reinhard Dummer, Katharina Spanaus Schlapbach, Günter Burg, Naohito Hatta, Silvio Hemmi, Jörg Willers, Hans-Uwe Simon, Günther F.L. Hofbauer, and Isabelle Daigle
- Subjects
Fas Ligand Protein ,Time Factors ,Cell Survival ,Apoptosis ,DNA Fragmentation ,Dermatology ,Ligands ,Fas ligand ,Metastasis ,Flow cytometry ,TNF-Related Apoptosis-Inducing Ligand ,Jurkat Cells ,Tumor Cells, Cultured ,Humans ,Medicine ,fas Receptor ,Melanoma ,Neoplasm Staging ,Membrane Glycoproteins ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,Tumor Necrosis Factor-alpha ,business.industry ,Flow Cytometry ,medicine.disease ,Immunohistochemistry ,Cell culture ,Tumor progression ,Lymphatic Metastasis ,Antigens, Surface ,Tumor Necrosis Factors ,Immunology ,Cancer research ,Tumor necrosis factor alpha ,Apoptosis Regulatory Proteins ,business - Abstract
Background: Apoptotic pathway aberrations are reported as important tumor progression factors in melanoma. Objective: Effect of soluble Fas ligand (sFasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on short-term cultured melanoma cell viability from different stages of melanoma. Results: Recombinant human FasL reduced viability after 18 h in a dose-dependent manner in 4 of 5 cell cultures from primary tumors and 1 of 9 cell cultures from metastatic melanoma (67.5 vs. 96.4%, p = 0.007). DNA fragmentation on flow cytometry confirmed apoptosis. Incubation with TRAIL had no effect on melanoma cell viability. Immunohistochemistry showed Fas in 3 of 4 primary and in 6 of 7 metastatic lesions, no FasL in primary lesions, and FasL in 5 of 7 metastatic lesions. Conclusion: Melanoma short-term cell cultures from primary tumors show decreased viability under FasL, but not TRAIL stimulation rather than short-term cell cultures derived from metastases.
- Published
- 2005
- Full Text
- View/download PDF